Martin government to reintroduce patent changes
- Abu Dhabi moves towards generic prescribing. // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p39
The article reports on the move of the Health Authority of Abu Dhabi in United Arab Emirates towards prescription of generic drugs in the country. It notes that Health Authority of Abu Dhabi also forces doctors throughout the area to use generic drugs by molecular name. However, the law in the...
- Pressure Builds on the U.S. to Facilitate Biogenerics. Scott, Alex // Chemical Week;3/21/2007, Vol. 169 Issue 10, p43
The article reports that almost 50 pro-patient groups in the U.S. are pressing the government to introduce legislation that would facilitate the sale of biologic generic drugs known as biogenerics or biosimilars. Congress debated new legislation that would enable the sale of biogenerics under...
- A tragically naive Canadian law for tragically neglected global health. Attaran, Amir // CMAJ: Canadian Medical Association Journal;6/5/2007, Vol. 176 Issue 12, p1726
The author reflects on the law passed by Canada's Parliament giving manufacturers of generic drugs to override the patents of brand name drugs for developing countries. He contends on the implementation of the law, which was made in support to the World Trade Organization's medical reform....
- AMCP objects. // Drug Topics;5/19/97, Vol. 141 Issue 10, p25
Reports that the Academy of Managed Care Pharmacy has signified its opposition to proposed legislation restricting generic substitution for certain drugs.
- N.J. companies warn Assembly on cost of bill. // Drug Store News;7/14/97, Vol. 19 Issue 11, pCP3
Reports that various generic pharmaceutical companies based in New Jersey have sent letters to the New Jersey Assembly urging members to defeat a bill restricting generic substitutions in the state.
- Governor approves NTI restrictions on generics. // Drug Store News;7/14/97, Vol. 19 Issue 11, pCP8
Reports that North Carolina's governor has signed into law a bill that limits the right of pharmacists to substitute generics.
- Sluggish generics entry prompts calls for European patent reform. Laursen, Lucas // Nature Medicine;Nov2009, Vol. 15 Issue 11, p1239
The article reports on the slow generics due to anticompetitive practices in pharmaceuticals prompting for European patent reform. The European Commission Directorate anticompetitive practices investigations has accused originators of using litigation to block competition from generic drug...
- Chains react swiftly to pending reimbursement cuts. // Chain Drug Review;4/26/2010, Vol. 32 Issue 8, p6
The article reports on the opposition of the drug store companies in Ontario to the legislation on reducing the reimbursement rate of generic drugs.
- Reforming Canada's Access to Medicines Regime. Esmail, Laura C. // CMAJ: Canadian Medical Association Journal;7/31/2007, Vol. 177 Issue 3, p270
A letter to the editor is presented in response to the commentary by Amir Attaran in the 2007 issue which significantly downplayed the importance of exceptions in patent law that permit generic drug production.
- Changes to India's patent law may deny cheap drugs to millions. Mudur, Ganapati // BMJ: British Medical Journal (International Edition);3/26/2005, Vol. 330 Issue 7493, p692
Looks at changes to patent laws in India which will impact the availability of generic drugs. Actions of the Indian parliament to introduce patents for medication, which will make cheaper generic drugs unavailable; Alignment of the proposed law with international standards for intellectual...